CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
This is a phase II, multi-center study to determine the efficacy and safety of first-line
CC-486 plus CHOP in patients with PTCL who have received no prior systemic therapy. The study
has a sample size of 20, and follows two-stage minimax design for primary efficacy analysis.